14. The antibody of claim 13, wherein the at least one increased effector function is selected from the group consisting of: increased Fc receptor binding affinity, increased antibody-mediated cellular cytotoxicity (ADCC), increased binding to NK cells, increased binding to macrophages, increased binding to monocytes, increased binding to polymorphonuclear cells, direct signaling inducing apoptosis, increased dendritic cell maturation, and increased T cell priming.

15. The ~~ABM or~~ antibody of claim 14, wherein the antibody has an increase in ADCC of at least about 40% to about 100% as compared to the non-glycoengineered parent antibody.

16. An isolated polynucleotide encoding the antibody of any one of claims 1-15.

17. A vector comprising the polynucleotide of claim 16.

18. A host cell comprising the vector of claim 17.

19. A composition comprising the antibody of any one of claims 1-15 and a pharmaceutically acceptable carrier.

20. An *in vitro* method of inducing cell lysis of a tumor cell, the method comprising contacting the tumor cell with the antibody of any of claims 1-15 or the composition of claim 19.

21. The *in vitro* method of claim 20, wherein the tumor cell is selected from the group consisting of a colorectal cancer cell, NSCLC (non-small cell lung cancer), gastric cancer cell, pancreatic cancer cell and breast cancer cell.

22. The *in vitro* method of claim 20, wherein the cell lysis is induced by antibody dependent cell cytotoxicity of the antibody.

23. The antibody of any one of claims 1-15 or the composition of claim 19 for use in treating a subject having a cancer that abnormally expresses CEA.

24. The antibody of any one of claims 1-15 or the composition of claim 19 for use in increasing survival time in a subject having a cancer that abnormally expresses CEA.

25. The antibody or composition of claim 23 or 24, wherein the cancer is selected from the group consisting of colorectal cancer, non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer and breast cancer.

26. The antibody or composition of any of claims 23-25, wherein the ~~ABM or~~ antibody or composition is for administration in combination with chemotherapy or radiation therapy.

27. The antibody or composition of any of claims 23-26, wherein the subject is a human.

28. Use of the antibody of any of claims 1-15 or the composition of claim 19 in the manufacture of a medicament for treating a subject having a cancer that abnormally expresses CEA.

29. The use of claim 28, wherein the cancer is selected from the group consisting of colorectal cancer, non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer and breast cancer.

30. The use of claims 28 or 29, wherein the antibody or composition is for administration in combination with chemotherapy or radiation therapy.

31. The use of any of claims 28-30, wherein the subject is a human.